Dr. George Zhi Cheng, MD, PhD

Dr. Cheng practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Cheng's NPI, 1316174568, was assigned on June 15, 2009. Dr. Cheng graduated from Icahn School Of Medicine At Mount Sinai in 2009. Dr. Cheng holds California license A166013.

Dr. Cheng's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Cheng's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Cheng is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cheng practices. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Cheng's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Cheng is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Cheng's licenses on file in 3 states: California, North Carolina and Massachusetts.

Dmand AI lists chronic obstructive pulmonary disease (COPD), lung resection, pleural effusion, pneumonia and upper respiratory infection (URI) among the conditions Dr. Cheng treats.

CMS data shows 1,003 Medicare services from Dr. Cheng across 21 procedure codes in 2024, for 339 Medicare patients. Medicare paid $76,020 for them.

CMS counts 339 Medicare patients who saw Dr. Cheng in 2024. The largest group is 65 to 74, with 156 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 37% are also on Medicaid. Their average risk score is 2.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cheng's median patient age at 66, with 50% women.

In 2024, Dr. Cheng wrote 64 Medicare Part D claims for 23 patients. 44% of them were for generic drugs. CMS names the drug for 31 of them, across 2 drugs with 11 or more claims each, at $429 in total drug cost. In 2019, CMS named 60 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Cheng for performance year 2024, reported as part of a group. Dr. Cheng accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cheng as offering telehealth.

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 67 papers to Dr. Cheng, published from 2008 to 2025. 2020 was the busiest year, with 6. The most frequent topics are Bronchoscopy, Lung Neoplasms and Proto-Oncogene Proteins c-akt. Dr. Cheng has published most often in J Bronchology Interv Pulmonol. Dr. Cheng's most frequent co-authors are George J. Cheng, MD, Momen Wahidi, MD and Erik Eduardo Folch, MD, MS.

Dmand AI links Dr. Cheng to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Neoplasm Metastasis, Pleural Effusion and Neoplastic Processes.

CMS Open Payments shows 493 general payments to Dr. Cheng from 27 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 41% of the total. Intuitive Surgical, Inc. paid the most, $167,041. It also lists 1 research payment totaling $2,150 in 2020.

Dr. Cheng graduated from Icahn School Of Medicine At Mount Sinai in 2009.

Dr. Cheng is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.